AJ Vaccines Will Contribute to the Global Polio Eradication With its Innovative Polio Vaccine

The new adjuvanted polio vaccine has been approved by the Danish
Medicines Agency, and the WHO prequalification is expected by the end
of 2019, enabling initial delivery of up to 100 million doses
globally via UN agencies in 2020-2024

Copenhagen, Denmark (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA
ONLY

AJ Vaccines today announced that its adjuvanted IPV vaccine has
gained marketing approval in Denmark by the Danish Medicines Agency.
The approval process was initiated in 2018 following positive results
from clinical trials involving almost 3,000 infants. The Danish
marketing approval paves the way for WHO prequalification with a view
to enable AJ Vaccines to deliver doses to UN agencies such as UNICEF
and PAHO early next year.

The marketing approval of the adjuvanted Inactivated Polio Vaccine
(IPV) is a major milestone in the ongoing efforts made under the
Global Polio Eradication Initiative established in 1988. The approved
vaccine provides active immunization against poliomyelitis by primary
vaccination in infants from the age of 6 weeks and for revaccination
of infants, children, adolescents and adults. The vaccine is based on
a proprietary formulation technology that allows a lower dose of
active substances, it is a well-tolerated and non-inferior
alternative to currently approved IPV vaccines.

"The approval of our new adjuvanted polio vaccine underlines the
world-class innovation and development capabilities of AJ Vaccines.
We are proud that our dedicated employees have deployed their
combined skills to develop a groundbreaking vaccine, which has the
potential to contribute greatly to the eradication of polio and reach
millions of infants in need of affordable and effective immunization
globally," said Jesper Helmuth Larsen, CEO of AJ Vaccines.

The marketing approval in Denmark and expected WHO
prequalification, combined with the recent investment in a state of
the art WHO GAPIII compliant polio vaccine manufacturing facility,
form a strong foundation for establishing AJ Vaccines as a major
contender in the global market for IPV vaccines during the global
eradication endgame and for routing immunizations after the
eradication.

"We expect the development and approval of the new vaccine will
have a positive impact on the lives of millions of people, while
simultaneously constituting a significant business potential and
growth opportunity for AJ Vaccines. We aim to launch the product
globally in early 2020 through partnerships with UNICEF and other
pooled procurement programs as well as directly to the private
market," said Jesper Helmuth Larsen.

The polio vaccine development project was initiated in 2013 in
cooperation with and financial support from the Bill & Melinda Gates
Foundation.

About AJ Vaccines

AJ Vaccines produces and sells vaccines from the company's
production site in central Copenhagen which is proud to have been
manufacturing vaccines since 1902. AJ Vaccines produces vaccines
against Diphtheria, Whooping Cough, Tetanus, Tuberculosis, Polio and
immunotherapy product for treatment of bladder cancer. The company
has some 730 employees and expects to expand its skilled workforce in
order to fulfill the ambitious growth plans.

See more at: http://www.ajvaccines.com/

ots Originaltext: AJ Vaccines
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Mr. Christian Malling
M: +45-2552-8170
E: cmal@ajvaccines.com

Original-Content von: AJ Vaccines, übermittelt durch news aktuell